MEMGEN LLC has a total of 20 patent applications. It decreased the IP activity by 76.0%. Its first patent ever was published in 2007. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are PIN PHARMA INC, BN IMMUNOTHERAPEUTICS INC and JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NAT INSTITUTE OF INFECTIOUS DISEASES.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 5 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | United States | 4 | |
#4 | Canada | 2 | |
#5 | China | 2 | |
#6 | Republic of Korea | 2 | |
#7 | Australia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Climate change adaptation technologies | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Cantwell Mark J | 15 |
#2 | Ewald Brett | 6 |
#3 | Chan Winnie M | 5 |
#4 | Robbins Joan M | 5 |
#5 | Cantwell Mark | 3 |
#6 | Hwu Patrick | 3 |
#7 | Singh Manisha | 3 |
#8 | Overwijk Willem W | 2 |
#9 | Prussak Charles E | 2 |
#10 | Overwijk Willem | 1 |
Publication | Filing date | Title |
---|---|---|
WO2018191369A1 | Methods of cd40 and toll like receptor immune activation | |
KR20190098215A | Armed Replication-Possible Oncolytic Adenoviruses | |
US2018169241A1 | Armed oncolytic viruses | |
WO2017079297A1 | Methods for treatment of cancer | |
WO2008070743A2 | Methods of increasing cancer sensitivity to chemotherapeutic agents using chimeric isf35 |